Drug Profile

Lipoic acid choline ester - Novartis

Alternative Names: EV-06; Lipoic acid choline ester 1.5%; Lipoic acid choline ester chloride; Thioctic acid choline ester; UNR 844; UNR844-Cl

Latest Information Update: 30 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Encore Vision
Developer Novartis
Class Carboxylic acids; Coenzymes; Esters; Eye disorder therapies; Fatty acids; Hepatoprotectants; Quaternary ammonium compounds; Sulfhydryl compounds; Thiophenes
Mechanism of Action Antioxidants; Free radical scavengers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 Jan 2023 NCT04806503; CTP-Push; Trial is already discontinued on the basis of MR hence not covered
28 Nov 2022 Discontinued - Phase-II for Presbyopia in Canada, Japan, Australia, USA (Ophthalmic)
14 Oct 2022 Novartis completes a phase II trial in Presbyopia in USA, Australia, Canada and Japan (Ophthalmic) (NCT04806503)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com